The BET Bromodomain inhibitor JQ1 radiosensitizes non-small cell lung cancer cells by upregulating p21

Radiotherapy is an important treatment modality in the management of locally advanced non-small cell lung cancer (NSCLC). However, radioresistance markedly impairs its efficacy in clinic. Bromodomain and extra-terminal (BET) bromodomain inhibitors have demonstrated dramatic antitumor activity in several preclinical human cancer models. In this study, we investigated for the first time the effect of JQ1, a novel BET Bromodomain inhibitor, on tumor cell radiosensitivity of NSCLC in vitro and in vivo.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2kFTDEV
via IFTTT